...24日，德国勃林格殷格翰公司对外宣布，欧洲药品评审中心人用药品委员会(CHMP)已发出正面评价，推荐森福罗/Mirapexin（普拉克索）用于不安腿综合征(RL)的治疗普拉克索是巴胺受体激动剂，目被批准用于帕金森病的治疗。
基于158个网页-相关网页
Mirapex ER 普拉克索缓释片
Dyskinesias developed in 31% of the levodopa patients, but only 10% of the Mirapex patients.
BBC: Parkinson's drug breakthrough
The researchers found that the impact of the drugs was less likely to wear off among the Mirapex patients.
During the first ten weeks of their treatment each was either given Mirapex or levadopa at the maximum tolerated dose.
应用推荐
模块上移
模块下移
不移动